Search Results for ''

published presentations and documents on DocSlides.

Digital health technology-derived clinical outcome assessments: considerations for regulatory decis

Digital health technology-derived clinical outcome assessments: considerations for regulatory decis

by jalin

Elektra Papadopoulos, MD, MPH. Acting Deputy Direc...

Striking the Balance: FDA Oncology’s Regulatory Perspective on Development of Agents for CIPN

Striking the Balance: FDA Oncology’s Regulatory Perspective on Development of Agents for CIPN

by rodriguez

Lynn Howie, MD, Medical Officer, DOP1. Supportive ...

WORLD HEALTH ASSEMBLY

WORLD HEALTH ASSEMBLY

by molly

S EVENT Y - FIFTH A 7 5 / A/ CONF ./ 9 A genda ite...

ScienceTranslationalMedicine

ScienceTranslationalMedicine

by naomi

www. .org 5 December 2012 Vol 4 Issue 163 163fs4...

Instructions Please fill out the template deck as completely as possible. Note that some informatio

Instructions Please fill out the template deck as completely as possible. Note that some informatio

by adia

Limit to 20 . slides excluding the title slide.. Y...

Society of Financial ExaminersCAREER DEVELOPMENT SEMINAR

Society of Financial ExaminersCAREER DEVELOPMENT SEMINAR

by lily

1EXAMINATIONS and ANALYSISAlways on My MindRegistr...

Diane L. Heinz, DVM, MBA

Diane L. Heinz, DVM, MBA

by debby-jeon

Director. Policy and Regulations Staff. Center fo...

7441 GI/2017 (1) jftLV

7441 GI/2017 (1) jftLV

by startlecisco

vlk/kj.kEXTRAORDINARYHkkx III

1 SYNERGY April 2017 DCDEE Update and New Initiatives DCDEE Mission

1 SYNERGY April 2017 DCDEE Update and New Initiatives DCDEE Mission

by cheryl-pisano

1 SYNERGY April 2017 DCDEE Update and New Initiat...

Risk Assessments: Patient Safety and Innovation

Risk Assessments: Patient Safety and Innovation

by liane-varnes

Innovation Discussion. 18. . July 2013. FDASIA G...

1 JAN Academy, USBLN July 9, 2018

1 JAN Academy, USBLN July 9, 2018

by tawny-fly

Josh Christianson, Project Director, PEAT. Adopti...

Biosimilars in emerging markets- regulatory and Commercial considerations

Biosimilars in emerging markets- regulatory and Commercial considerations

by jane-oiler

OMIC Group. Biosimilars 2104. Hyderabad. India. 2...

EXPERT LEVEL TRAINING ON

EXPERT LEVEL TRAINING ON

by cheryl-pisano

TELECOM NETWORK COST . MODELLING . FOR THE HIPSSA...

Tina Morrison U.S. FDA March 23, 2017

Tina Morrison U.S. FDA March 23, 2017

by celsa-spraggs

FDA Modeling and Simulation Working Group. Sponso...

Diane L. Heinz, DVM, MBA

Diane L. Heinz, DVM, MBA

by olivia-moreira

Director. Policy and Regulations Staff. Center fo...

Rectal artesunate Strides

Rectal artesunate Strides

by conchita-marotz

. Shasun. Pyronaridine-. artesunate . granules. ...

NMLS 2.0 Update North American Collection Agency Regulatory Association

NMLS 2.0 Update North American Collection Agency Regulatory Association

by pasty-toler

(NACARA). October 3, 2017. Outline. What is NMLS?...

On ICH Feb. 13, 2013 Toshi

On ICH Feb. 13, 2013 Toshi

by faustina-dinatale

. Tominaga. Ph. D.. Food and Drug Evaluation Ce...

REGULATORY REQUIREMENTS FOR PREFORMULATION STUDIES

REGULATORY REQUIREMENTS FOR PREFORMULATION STUDIES

by pamella-moone

INTRODUCTION:. Prior to nomination into full deve...

Cannabis – County Regulatory Challenges

Cannabis – County Regulatory Challenges

by conchita-marotz

Josh Huntsinger, Placer County Agricultural Commi...